Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Jun 14, 2023

BUY
$3.35 - $5.55 $10,147 - $16,810
3,029 New
3,029 $10.1 Million
Q3 2022

Mar 30, 2023

BUY
$3.35 - $5.55 $780 - $1,293
233 Added 8.33%
3,029 $10,000
Q3 2022

Nov 14, 2022

BUY
$3.35 - $5.55 $10,147 - $16,810
3,029 New
3,029 $10,000
Q2 2022

Aug 11, 2022

SELL
$3.12 - $7.52 $8,723 - $21,025
-2,796 Closed
0 $0
Q1 2022

Jun 20, 2023

BUY
$6.26 - $14.42 $17,502 - $40,318
2,796 New
2,796 $20,000
Q1 2022

Mar 30, 2023

SELL
$6.26 - $14.42 $56,684 - $130,573
-9,055 Reduced 76.41%
2,796 $20,000
Q1 2022

May 12, 2022

SELL
$6.26 - $14.42 $56,684 - $130,573
-9,055 Reduced 76.41%
2,796 $20,000
Q4 2021

Jun 21, 2023

BUY
$11.35 - $21.18 $134,508 - $251,004
11,851 New
11,851 $161,000
Q3 2021

Jun 21, 2023

BUY
$18.17 - $24.7 $215,332 - $292,719
11,851 New
11,851 $248,000
Q2 2021

Jun 21, 2023

BUY
$20.08 - $29.02 $237,968 - $343,916
11,851 New
11,851 $283,000
Q2 2021

Mar 30, 2023

BUY
$20.08 - $29.02 $151,644 - $219,159
7,552 Added 175.67%
11,851 $283,000
Q2 2021

Aug 16, 2021

BUY
$20.08 - $29.02 $237,887 - $343,799
11,847 Added 296175.0%
11,851 $284,000
Q1 2021

Jun 26, 2023

BUY
$27.0 - $32.48 $116,073 - $139,631
4,299 New
4,299 $126 Million
Q1 2021

Mar 30, 2023

SELL
$27.0 - $32.48 $14,040 - $16,889
-520 Reduced 10.79%
4,299 $125,000
Q1 2021

May 14, 2021

SELL
$27.0 - $32.48 $130,005 - $156,391
-4,815 Reduced 99.92%
4 $126,000
Q4 2020

Jun 22, 2023

BUY
$26.68 - $38.23 $128,570 - $184,230
4,819 New
4,819 $143,000
Q4 2020

Mar 30, 2023

BUY
$26.68 - $38.23 $128,570 - $184,230
4,819 New
4,819 $143,000
Q4 2020

Feb 16, 2021

BUY
$26.68 - $38.23 $128,570 - $184,230
4,819 New
4,819 $144,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $55.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.